<DOC>
	<DOC>NCT00120523</DOC>
	<brief_summary>The primary purpose of this study is to investigate the safety of pimecrolimus cream 1% in the long-term treatment (up to 5 years) of atopic dermatitis (eczema) in patients less than 12 months of age compared to topical corticosteroids (TCS).</brief_summary>
	<brief_title>5-Year Safety Study of Pimecrolimus Cream 1% in Infants 3 - 12 Months of Age With Mild to Moderate Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Aged 3 to &lt; 12 months Diagnosis of AD fulfilling the diagnostic criteria of Seymour AD affecting at least 5% total body surface area Investigator's Global Assessment (IGA) score of 2 or 3, corresponding to mildtomoderate disease at baseline Informed consent Phototherapy, systemic therapy (e.g., immunosuppressants, cytostatics), systemic corticosteroids within 4 weeks Topical tacrolimus or pimecrolimus within 2 weeks Topical therapy (e.g., tar, topical corticosteroids) within 3 days Immunocompromised (e.g., lymphoma, AIDS, WiskottAldrich Syndrome) or have a history of malignant disease Active acute viral skin infection (e.g. herpes simplex, herpes zoster, chicken pox), and/or clinically infected AD Failure to thrive (e.g., weight or height/length below the 5th percentile) or developmental abnormalities such as head circumference less than 5th and more than 95th percentile Known hypersensitivity to any ingredient of pimecrolimus cream 1% or topical corticosteroids Clinical conditions other than AD that according to investigator can interfere with the evaluation</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Months</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Atopic dermatitis, children, infants, pimecrolimus</keyword>
</DOC>